Displaying 51 - 68 of 68 results
Released Company Title Industry Topic
30 Sep 2022
08:45 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million 20103010 Biotechnology Change in Capital
26 Sep 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022 20103010 Biotechnology Other subject
31 Jul 2022
18:05 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022 20103010 Biotechnology Trends / Analyses
31 Jul 2022
18:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O 20103010 Biotechnology Trends / Analyses
23 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD 20103010 Biotechnology Trends / Analyses
22 Jun 2022
19:13 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022 20103010 Biotechnology General meeting / Board Meeting
15 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress 20103010 Biotechnology Commercial results
08 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022 20103010 Biotechnology Other subject
11 May 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022 20103010 Biotechnology General meeting / Board Meeting
28 Apr 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress 20103010 Biotechnology Commercial results, Other subject
21 Apr 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022 20103010 Biotechnology Commercial results
20 Apr 2022
12:01 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences 20103010 Biotechnology Meetings / events
01 Apr 2022
08:47 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million 20103010 Biotechnology Change in Capital
31 Mar 2022
17:45 CEST
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement 20103010 Biotechnology Change in Capital
07 Mar 2022
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference 20103010 Biotechnology Meetings / events
28 Feb 2022
01:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease 20103010 Biotechnology Other subject
04 Jan 2022
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences 20103010 Biotechnology Meetings / events
22 Dec 2021
07:00 CET
VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease 20103010 Biotechnology Other subject